EphA2 overexpression reduces H2O2-induced damage of lens epithelial cells Cellular, Molecular and Developmental Genetics

Age-related cataract (ARC) is a progressive lens opacification that occurs from middle to old age. Eph-receptor tyrosinekinase-type A2 (EphA2) has been reported to be associated with ARC. This work aims to investigate the molecular mechanism of EphA2 in ARC. We treated human lens epithelial cells (S...

Full description

Saved in:
Bibliographic Details
Published inGenetics and molecular biology Vol. 44; no. 3; p. 1
Main Authors Ji, Qingshan, Liu, Jing, Wang, Guifang, Liu, Lian, Zhong, Jingxiang
Format Journal Article
LanguageEnglish
Published Ribeirao Preto Sociedade Brasileira de Genetica 01.01.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Age-related cataract (ARC) is a progressive lens opacification that occurs from middle to old age. Eph-receptor tyrosinekinase-type A2 (EphA2) has been reported to be associated with ARC. This work aims to investigate the molecular mechanism of EphA2 in ARC. We treated human lens epithelial cells (SRA01/04) with different concentration of H2O2 to induce lens epithelial cell damage. Then, we found that H2O2 treatment significantly suppressed cell viability and enhanced the expression of EphA2 in the SRA01/04 cells. H2O2 treatment repressed cell viability and enhanced the levels of reactive oxygen species (ROS) in SRA01/04 cells, which was partly abolished by EphA2 up-regulation. Moreover, EphA2 overexpression reduced H2O2-induced apoptosis of SRA01/04 cells. EphA2 up-regulation caused an up-regulation of Bcl-2, and repressed the expression of Bax and Cleaved-caspase-3 in the SRA01/04 cells following H2O2 treatment. In conclusion, our data confirm that EphA2 overexpression enhances cell viability and inhibits apoptosis in the H2O2-treated SRA01/04 cells, thereby reducing H2O2-induced damage of lens epithelial cells. Thus, this work provides new insights into the mechanism of EphA2 in ARC.
ISSN:1415-4757
1678-4685
DOI:10.1590/1678-4685-GMB-2020-0414